Tumor immunotherapy was designed to suppress the binding of tumor PD-L1 to PD-1 on the T cell surface, then reactive the inactivated immune cells, and eventually realize the role of recognizing and eliminating tumor cells more effectively. This evidence concerns the gene PDCD1 and neoplasm.